Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study | Zendy

Katharina Sinn | Zendy; Berta Mosleh | Zendy; Ariane Steindl | Zendy; S. Zoechbauer-Mueller | Zendy; Karin Dieckmann | Zendy; Joachim Widder | Zendy; E. Steiner | Zendy; Walter Klepetko | Zendy; Konrad Höetzenecker | Zendy; Viktória László | Zendy; Balazs Doeme | Zendy; Thomas Klikovits | Zendy; Mir Alireza Hoda | Zendy

Open Access

Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study

Author(s) -

Katharina Sinn,

Berta Mosleh,

Ariane Steindl,

S. Zoechbauer-Mueller,

Karin Dieckmann,

Joachim Widder,

E. Steiner,

Walter Klepetko,

Konrad Höetzenecker,

Viktória László,

Balazs Doeme,

Thomas Klikovits,

Mir Alireza Hoda

Publication year - 2022

Publication title -

esmo open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.409

H-Index - 31

ISSN - 2059-7029

DOI - 10.1016/j.esmoop.2022.100466

Subject(s) - medicine , neoadjuvant therapy , hazard ratio , lung cancer , stage (stratigraphy) , pneumonectomy , propensity score matching , chemotherapy , retrospective cohort study , chemoradiotherapy , single center , surgery , cohort , oncology , gastroenterology , cancer , confidence interval , breast cancer , biology , paleontology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog